Coherus BioSciences Inc. (NASDAQ:CHRS) shares traded 2.24% higher at $4.56 on Wall Street last session.
In accordance with the data, 9 analysts cover Coherus BioSciences Inc. (NASDAQ:CHRS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $24.00 and a low of $8.00, we find $12.00. Given the previous closing price of $4.46, this indicates a potential upside of 169.06 percent. CHRS stock price is now -32.47% away from the 50-day moving average and -44.88% away from the 200-day moving average. The market capitalization of the company currently stands at $364.89M.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
It has been rated a hold by 2 analysts and a buy by 6. Brokers who have rated the stock have averaged $15.00 as their price target over the next twelve months.
.
A total of 1.88% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CHRS stock. A new stake in Coherus BioSciences Inc. shares was purchased by MARSHALL WACE, LLP during the first quarter worth $2,613,000. PHOCAS FINANCIAL CORP. invested $744,000 in shares of CHRS during the first quarter. In the first quarter, CAXTON ASSOCIATES LP acquired a new stake in Coherus BioSciences Inc. valued at approximately $512,000. PROFUND ADVISORS LLC acquired a new stake in CHRS for approximately $352,000. NEW YORK LIFE INVESTMENT MANAGEMENT LLC purchased a new stake in CHRS valued at around $332,000 in the second quarter. In total, there are 257 active investors with 103.23% ownership of the company’s stock.
Coherus BioSciences Inc. (NASDAQ: CHRS) opened at $4.4600 on Tuesday. During the past 12 months, Coherus BioSciences Inc. has had a low of $4.36 and a high of $14.11. The fifty day moving average price for CHRS is $6.7164 and a two-hundred day moving average price translates $8.2368 for the stock.
The latest earnings results from Coherus BioSciences Inc. (NASDAQ: CHRS) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.75, missing analysts’ expectations of -$0.57 by -0.18. This compares to -$1.24 EPS in the same period last year. The company reported revenue of $32.44 million for the quarter, compared to $60.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -46.04 percent. For the current quarter, analysts expect CHRS to generate $54.93M in revenue.
Coherus BioSciences Inc.(CHRS) Company Profile
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
